NCT01666652View on ClinicalTrials.gov

A Two-dose Primary Vaccination Study of a Tetravalent Dengue Virus Purified Inactivated Vaccine vs. Placebo in Healthy Adults

PHASE1CompletedINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

September 30, 2012

Primary Completion Date

September 30, 2015

Study Completion Date

November 30, 2017

Conditions
Dengue Fever
Interventions
BIOLOGICAL

4 µg TDENV-PIV with Alum adjuvant

BIOLOGICAL

1 µg TDENV-PIV with AS03B1 adjuvant

OTHER

Phosphate buffered saline

BIOLOGICAL

1 µg TDENV-PIV with Alum adjuvant

BIOLOGICAL

1 µg TDENV-PIV with AS01E1 adjuvant

Trial Locations (1)

20910-7500

WRAIR, Clinical Trials Center, Silver Spring

Sponsors

Collaborators (1)

GlaxoSmithKline
All Listed Sponsors
collaborator

GlaxoSmithKline

INDUSTRY

collaborator

Walter Reed Army Institute of Research (WRAIR)

FED

lead

U.S. Army Medical Research and Development Command

FED

NCT01666652 - A Two-dose Primary Vaccination Study of a Tetravalent Dengue Virus Purified Inactivated Vaccine vs. Placebo in Healthy Adults | Biotech Hunter | Biotech Hunter